Asuragen

About Asuragen

Asuragen, Inc. is a biotechnology company specializing in molecular diagnostics and research tools. The company serves clinical laboratories, pharmaceutical companies, and research institutions, primarily in the fields of genetics and oncology. Operating in the molecular diagnostics market, Asuragen develops and commercializes diagnostic kits and reagents that enable the detection and quantification of genetic mutations and pathogenic sequences.

Asuragen's product portfolio includes FDA-cleared tests such as the Fragile X Dx and Carrier Screen Kit, which is the first and only test for detecting expanded pathogenic repeat sequences cleared by the FDA. The company also offers the PCR CE SMN1/2 Plus Kit for comprehensive analysis of SMN1 and SMN2 genes, and the PCR CE HTT Kit for detecting CAG trinucleotide repeats associated with Huntington's Disease. Additionally, Asuragen has developed the Armored RNA SARS-CoV-2 Control to support COVID-19 assay development.

The business model focuses on selling diagnostic kits and reagents to clinical and research laboratories, generating revenue through product sales and partnerships with pharmaceutical companies for companion diagnostics development.